A growing demand for highly potent active pharmaceutical ingredients (HPAPIs), twinned with the prevalence of oncological, immunosuppressant and hormone-based products is fuelling need for high potency handling capabilities.
ChargePoint Technology's very own Michael Avraam discusses the potential issues with containment performance testing, data collection and interpretation and how these may affect end user with Pharma Focus Asia. You can read the full article (pg.50) here.
With the demand in high potency containment systems continuing to rise, it has never been more critical to have adequate containment strategies and appropriate verification in place. Yet, it is also crucial to understand the variations in validation testing available and the potential challenges and differences posed by the interpretation of results.
Our global product manager, Michael Avraam speaks to European Pharmaceutical Manufacturer about the considerations surrounding containment performance testing and data collection methods. Michael also discusses the techniques available to help ensure efficient containment performance testing moving forward. You can read the full article in EPM here.
Demand for high potent active pharmaceutical ingredients is driving the need for high potency handling capabilities.
In this latest article with EPM Magazine, ChargePoint Technology's Global Product Manager for Containment, Mike Avraam, discusses this growing sector in detail and how the need for change in manufacturing facilities has changed over the last 10 years.
Current containment methods were reviewed in a presentation delivered last month at the ISPE Singapore Conference and Exhibition by Michael Avraam, Global Product Manager for Containment at ChargePoint Technology. Read more...